Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

dc.creatorItkin, Boris
dc.creatorGarcia, Agustin
dc.creatorStraminsky, Samanta
dc.creatorAdelchanow, Eduardo Daniel
dc.creatorPereyra, Matias
dc.creatorHaab, Gabriela Acosta
dc.creatorBardach, Ariel Esteban
dc.date2021-09
dc.date.accessioned2023-08-31T00:19:23Z
dc.date.available2023-08-31T00:19:23Z
dc.identifierhttp://hdl.handle.net/11336/184501
dc.identifierItkin, Boris; Garcia, Agustin; Straminsky, Samanta; Adelchanow, Eduardo Daniel; Pereyra, Matias; et al.; Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis; Public Library of Science; Plos One; 16; 9; 9-2021; 1-24
dc.identifier1932-6203
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8543312
dc.descriptionThe reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
dc.descriptionFil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
dc.descriptionFil: Garcia, Agustin. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
dc.descriptionFil: Straminsky, Samanta. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
dc.descriptionFil: Adelchanow, Eduardo Daniel. Hospital Nacional Profesor Alejandro Posadas.; Argentina
dc.descriptionFil: Pereyra, Matias. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
dc.descriptionFil: Haab, Gabriela Acosta. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;
dc.descriptionFil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherPublic Library of Science
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257976
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0257976
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttps://creativecommons.org/licenses/by/2.5/ar/
dc.subjectINMUNOHISTOCHEMISTRY
dc.subjectMALIGNANT TUMORS
dc.subjectHISTOLOGY
dc.subjectUTERINE CANCER
dc.subjecthttps://purl.org/becyt/ford/3.3
dc.subjecthttps://purl.org/becyt/ford/3
dc.titlePrevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución